Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Measuring and improving adherence to osteoporosis pharmacotherapy.

Cadarette SM, Burden AM.

Curr Opin Rheumatol. 2010 Jul;22(4):397-403. doi: 10.1097/BOR.0b013e32833ac7fe. Review.

2.

Role of the Pharmacist in Medication Therapy Management Services in Patients With Osteoporosis.

Murphy-Menezes M.

Clin Ther. 2015 Jul 1;37(7):1573-86. doi: 10.1016/j.clinthera.2015.03.023. Epub 2015 Apr 23. Review.

PMID:
25913920
3.

Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.

Balasubramanian A, Tosi LL, Lane JM, Dirschl DR, Ho PR, O'Malley CD.

J Bone Joint Surg Am. 2014 Apr 2;96(7):e52. doi: 10.2106/JBJS.L.01781.

PMID:
24695929
4.

The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.

Hiligsmann M, Boonen A, Rabenda V, Reginster JY.

Expert Rev Pharmacoecon Outcomes Res. 2012 Apr;12(2):159-66. doi: 10.1586/erp.12.8. Review.

PMID:
22458617
5.

Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis (SARA).

Landfeldt E, Ström O, Robbins S, Borgström F.

Osteoporos Int. 2012 Feb;23(2):433-43. doi: 10.1007/s00198-011-1549-6. Epub 2011 Feb 1.

PMID:
21286686
6.

Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review.

Gleeson T, Iversen MD, Avorn J, Brookhart AM, Katz JN, Losina E, May F, Patrick AR, Shrank WH, Solomon DH.

Osteoporos Int. 2009 Dec;20(12):2127-34. doi: 10.1007/s00198-009-0976-0. Epub 2009 Jun 5. Review.

7.

Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims.

Copher R, Buzinec P, Zarotsky V, Kazis L, Iqbal SU, Macarios D.

Curr Med Res Opin. 2010 Apr;26(4):777-85. doi: 10.1185/03007990903579171.

PMID:
20095797
8.

Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.

Cramer JA, Silverman S.

Am J Med. 2006 Apr;119(4 Suppl 1):S12-7. Review.

PMID:
16563936
9.

Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis.

Baio G, Barbagallo M, D'Avola G, Di Luccio A, Di Tanna GL, Falaschi P, Iolascon G, Malavolta N, Robbiati F, Ulivieri FM.

Expert Opin Pharmacother. 2011 Feb;12(2):257-68. doi: 10.1517/14656566.2011.537259.

PMID:
21226636
10.
11.

Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.

Rabenda V, Hiligsmann M, Reginster JY.

Expert Opin Pharmacother. 2009 Oct;10(14):2303-15. doi: 10.1517/14656560903140533. Review.

PMID:
19640210
12.

Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.

Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM.

Osteoporos Int. 2010 Nov;21(11):1943-51. doi: 10.1007/s00198-009-1134-4. Epub 2009 Dec 5. Review.

PMID:
19967338
14.

Impact of interactive voice response technology on primary adherence to bisphosphonate therapy: a randomized controlled trial.

Cizmic AD, Heilmann RM, Milchak JL, Riggs CS, Billups SJ.

Osteoporos Int. 2015 Aug;26(8):2131-6. doi: 10.1007/s00198-015-3116-z. Epub 2015 May 9.

PMID:
25956282
15.

The economics of improving medication adherence in osteoporosis: validation and application of a simulation model.

Patrick AR, Schousboe JT, Losina E, Solomon DH.

J Clin Endocrinol Metab. 2011 Sep;96(9):2762-70. doi: 10.1210/jc.2011-0575. Epub 2011 Jul 6.

16.

Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group.

Hiligsmann M, Salas M, Hughes DA, Manias E, Gwadry-Sridhar FH, Linck P, Cowell W.

Osteoporos Int. 2013 Dec;24(12):2907-18. doi: 10.1007/s00198-013-2364-z. Epub 2013 May 1. Review.

PMID:
23636230
17.

Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario Osteoporosis Strategy's fracture clinic screening program.

Beaton DE, Dyer S, Jiang D, Sujic R, Slater M, Sale JE, Bogoch ER; Osteoporosis Fracture Clinic Screening Program Evaluation Team..

Osteoporos Int. 2014 Jan;25(1):289-96. doi: 10.1007/s00198-013-2430-6. Epub 2013 Jun 21.

PMID:
23794044
18.

Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication.

Stuurman-Bieze AG, Hiddink EG, van Boven JF, Vegter S.

Osteoporos Int. 2014 Jun;25(6):1807-12. doi: 10.1007/s00198-014-2659-8. Epub 2014 Feb 26.

PMID:
24570297
19.

Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.

Soong YK, Tsai KS, Huang HY, Yang RS, Chen JF, Wu PC, Huang KE.

Osteoporos Int. 2013 Feb;24(2):511-21. doi: 10.1007/s00198-012-1984-z. Epub 2012 May 16.

PMID:
22588182
20.

The impact of teriparatide adherence and persistence on fracture outcomes.

Yu S, Burge RT, Foster SA, Gelwicks S, Meadows ES.

Osteoporos Int. 2012 Mar;23(3):1103-13. doi: 10.1007/s00198-011-1843-3. Epub 2011 Dec 8.

PMID:
22159748

Supplemental Content

Support Center